denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: educational grants from CTI Biopharma; Geron Corporation; GSK; and Karyopharm Therapeutics. Provided by Clinical Care Options, LLC.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Diseases, Therapies
Hematology Disease Topics & Pathways:
Diseases, Therapies
Friday, December 8, 2023: 11:00 AM-2:00 PM
San Diego Ballroom AB
(Marriott Marquis San Diego Marina)
Speakers:
Jean-Jacques Kiladjian, MD, PhD, Hopital Saint-Louis
and
Abdulraheem Yacoub, MD, The University of Kansas
Disclosures:
Kiladjian: Abbvie: Membership on an entity's Board of Directors or advisory committees; AOP Orphan Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Incyte Corporation: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; AbbVie, AOP Health, Bristol-Myers Squibb, GlaxoSmithKline, Incyte, Novartis, Pharmaessentia.: Consultancy. Yacoub: Incyte Corporation: Consultancy; Protagonist Therapeutics, Inc.: Consultancy; CTI Pharma: Consultancy; Pharmaessentia: Consultancy; Pfizer: Consultancy; Novartis: Consultancy; Gilead: Consultancy; Apellis: Consultancy; Acceleron Pharma, Inc.: Consultancy; Servier: Consultancy; Notable Labs: Consultancy; AbbVie Inc.: Consultancy; AbbVie, Acceleron, Apellis, CTI Pharma, Gilead, Incyte, Notable Labs, Novartis, Pfizer, PharmaEssentia, Servier.: Consultancy.
During this symposium experts will review the latest data and provide practical insights on the diagnosis, risk stratification, and management of myelofibrosis (MF). As appropriate, each topic of the symposium will include a case review, didactic presentation, and interactive panel and audience engagement with opportunity for those in attendance to text questions and challenging case scenarios to the panelists. In this Master Class symposium participants can expect to interact with the experts as well as colleagues seated at your table to discuss data, guidelines, and disease factors that impact therapeutic decisions and then debate treatment recommendations for cases presented during the program. Discussion topics include: Partnering With Patients to Improve Outcomes and Quality of Life; Selecting Initial Treatment for Patients With Myelofibrosis; Recognizing Patterns of Suboptimal Response to Firstline MF Treatment; Beyond the First Line: Disease Progression or Intolerance to Initial Therapy; A Look to the Future: What’s on the Horizon in MF Treatment?
See more of: Friday Satellite Symposia